Genomics Personalized Health Market Report 2026

The genomics personalized health market size has grown rapidly in recent years. It will grow from $18.5 billion in 2025 to $21.46 billion in 2026 at a compound annual growth rate (CAGR) of 16%. The growth in the historic period can be attributed to advancements in sequencing technologies, declining costs of genomic testing, expansion of clinical genomics research, growth of personalized medicine initiatives, increasing availability of bioinformatics tools.

The genomics personalized health market size is expected to see rapid growth in the next few years. It will grow to $36.55 billion in 2030 at a compound annual growth rate (CAGR) of 14.2%. The growth in the forecast period can be attributed to increasing adoption of population-scale genomics programs, rising investments in AI-driven diagnostics, expansion of personalized therapeutics, growing integration of genomics in routine clinical care, increasing focus on predictive healthcare models. Major trends in the forecast period include increasing adoption of genomic data analytics platforms, rising use of AI for variant interpretation, expansion of personalized treatment pathways, growing integration of genomics in preventive healthcare, enhanced focus on precision diagnostics.

The increasing demand for personalized medicine is anticipated to drive the growth of the genomics personalized health market in the coming years. Personalized medicine, also referred to as precision medicine, is a healthcare approach that customizes medical treatment and practices according to the unique characteristics of each patient. This rising demand is fueled by a shift toward preventive healthcare, enhanced treatment outcomes, patient engagement and empowerment, economic advantages, and the growing prevalence of chronic and complex diseases. Genomics personalized health plays a key role in advancing personalized medicine by using individual genetic information to guide medical care, including prevention, diagnosis, treatment, and monitoring. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six approvals in 2022. Consequently, the increasing interest in personalized medicine is driving the growth of the genomics personalized health market.

Major companies in the genomics personalized health market are concentrating on developing innovative solutions, such as cloud-based software for tertiary analysis of clinical next-generation sequencing (NGS) data, to strengthen their market position. Clinical NGS data refers to genetic information obtained through sequencing technologies that enable high-throughput and detailed analysis of DNA or RNA samples in a clinical setting. For instance, in March 2023, Illumina, a US-based biotechnology firm specializing in DNA sequencing and array technologies, launched Connected Insights, a cloud-based platform for tertiary analysis of clinical NGS data. This platform is designed to streamline interpretation and reporting, particularly in oncology, and supports comprehensive genomic profiling. By integrating multiple third-party knowledge bases, Connected Insights enhances precision in data analysis and improves the efficiency of precision care initiatives.

In January 2023, Agilent Technologies Inc., a US-based life sciences and analytical instrumentation company, acquired Avida Biomed Inc. for US$30 million. This acquisition aims to strengthen Agilent’s next-generation sequencing (NGS) capabilities and expand its presence in the rapidly growing clinical research and diagnostics markets. Avida Biomed Inc., a US-based biotechnology company, specializes in genomics and personalized health.

Major companies operating in the genomics personalized health market are Illumina Inc., Quest Diagnostics, Exact Sciences Corporation, Natera Inc., Adaptive Biotechnologies Corporation, Myriad Genetics Inc., Pacific Biosciences of California Inc., Personalis Inc., Invitae Corporation, GRAIL Inc., XCode Life Sciences Private Limited, BGI Genomics Co. Ltd., Genetic Technologies Limited, Eastern Biotech and Life Sciences, Tempus AI, Guardant Health, Freenome, Color Genomics, Helix, NantOmics, Novogenia GmbH, Clear Labs.

North America was the largest region in the personalized health market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomics personalized health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the genomics personalized health market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the genomics personalized health market by increasing costs of imported sequencing instruments, reagents, bioinformatics software, and high-performance computing infrastructure. Diagnostic and research institutions in North America and Europe are most affected due to reliance on globally sourced genomic technologies, while Asia-Pacific faces higher costs for expanding precision medicine programs. These tariffs are increasing testing costs and slowing infrastructure expansion. However, they are also encouraging domestic manufacturing of sequencing equipment, regional reagent production, and localized genomics data platforms, strengthening long-term ecosystem resilience.

The genomics personalized health market research report is one of a series of new reports that provides genomics personalized health market statistics, including genomics personalized health industry global market size, regional shares, competitors with a genomics personalized health market share, detailed genomics personalized health market segments, market trends and opportunities, and any further data you may need to thrive in the genomics personalized health industry. This genomics personalized health market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Genomics personalized health involves customizing medical care and treatments based on an individual's genomic data, taking into account their specific genetic characteristics, lifestyle choices, and environmental factors. This method utilizes progress in genomics, bioinformatics, and personalized medicine to offer more accurate and efficient healthcare solutions personalized to each person's genetic inclinations, susceptibilities, and responses to treatment.

The primary test types of genomics personalized health comprise oncology testing, infectious disease testing, orphan disease testing, autoimmune disease testing, obstetrics testing, and others. Oncology testing involves employing genetic testing methods to identify cancer and ascertain its unique attributes, utilizing technologies such as NGS platforms, RT-PCR, microarray, and genetic analyzers. These tests cater to end users such as academic research institutes, diagnostic centers, and others.

The genomics personalized health market consists of revenues earned by entities by providing services such as genomic sequencing, bioinformatics analysis, genetic testing, and consulting services. The market value includes the value of related goods sold by the service provider or included within the service offering. The genomics personalized health market also includes sales of DNA sequencing kits, genomic data management solutions, pharmacogenomics tests, personalized wellness and nutrition products, and companion diagnostics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.